Critical appraisal of belinostat in the management of T-cell lymphoma – patient considerations
Andrew Bodiford,1 Mahsa S Talbott,1 Nishitha M Reddy,2 1Department of Pharmacy, 2Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA Abstract: The histone deacetylase inhibitor (HDACi), belinostat, is an emerging and novel therapeutic...
Enregistré dans:
| Auteurs principaux: | , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Dove Medical Press
2015
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/7f9b2bb7038a46f3b3e17cfcefd11a9f |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|